よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (41 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
72. Tamma PD, Bergman Y, Jacobs EB. et al. Comparing the activity of novel antibiotic agents
against carbapenem-resistant Enterobacterales clinical isolates. Infect Control Hosp
Epidemiol. 2023 May;44(5):762-767.
73. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal
Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP),
European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious
Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology
(ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases
Pharmacists (SIDP). Pharmacotherapy 2019;39:10-39.
74. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and Safety of High
Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and MetaAnalysis. Adv Ther 2020 Mar;37(3):1049-1064.
75. De Pascale G, Lisi L, Ciotti GMP. et al. Pharmacokinetics of high-dose tigecycline in critically
ill patients with severe infections. Ann Intensive Care. 2020 Jul;10(1):94.
76. Paul M, Daikos GL, Durante-Mangoni E. et al. Colistin alone versus colistin plus meropenem
for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria:
an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400.
77. Pascale R, Giannella M, Bartoletti M, Viale P, Pea F. Use of meropenem in treating
carbapenem-resistant Enterobacteriaceae infections. Expert Rev Anti Infect Ther. 2019
Oct;17(10):819-827.
78. コリスチンの適正使用に関する指針―改訂版―, 日本化学療法学会雑誌;63(3):290-329. 2015.
at https://www.chemotherapy.or.jp/uploads/files/guideline/colistin_guideline_update.pdf.)
79. チゲサイクリン適正使用のための手引き 日本化学療法学会雑誌; 62(3):311-366.
2014;62:311-66.
80. Tamma PD, Han JH, Rock C. et al. Carbapenem therapy is associated with improved
survival compared with piperacillin-tazobactam for patients with extended-spectrum betalactamase bacteremia. Clin Infect Dis. 2015 May;60(9):1319-1325.
81. NICE Guideline. Sepsis: recognition, diagnosis and early management. 2017. at
https://www.nice.org.uk/guidance/ng51/resources/sepsis-recognition-diagnosis-and-earlymanagement-pdf-1837508256709.)
82. Heil EL, Bork JT, Abbo LM. et al. Optimizing the Management of Uncomplicated GramNegative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process.
Open Forum Infect Dis. 2021 Oct;8(10):ofab434.
83. Poutsiaka DD, Davidson LE, Kahn KL, Bates DW, Snydman DR, Hibberd PL. Risk factors for
death after sepsis in patients immunosuppressed before the onset of sepsis. Scand J Infect
Dis. 2009;41(6-7):469-479.
84. Evans L, Rhodes A, Alhazzani W. et al. Surviving sepsis campaign: international guidelines
for management of sepsis and septic shock 2021. Intensive Care Med. 2021
Nov;47(11):1181-1247.
85. 厚生労働省 薬剤耐性緑膿菌感染症. at https://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou11/01-05-42-01.html.)
41
第三版
別冊
72. Tamma PD, Bergman Y, Jacobs EB. et al. Comparing the activity of novel antibiotic agents
against carbapenem-resistant Enterobacterales clinical isolates. Infect Control Hosp
Epidemiol. 2023 May;44(5):762-767.
73. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal
Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP),
European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious
Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology
(ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases
Pharmacists (SIDP). Pharmacotherapy 2019;39:10-39.
74. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and Safety of High
Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and MetaAnalysis. Adv Ther 2020 Mar;37(3):1049-1064.
75. De Pascale G, Lisi L, Ciotti GMP. et al. Pharmacokinetics of high-dose tigecycline in critically
ill patients with severe infections. Ann Intensive Care. 2020 Jul;10(1):94.
76. Paul M, Daikos GL, Durante-Mangoni E. et al. Colistin alone versus colistin plus meropenem
for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria:
an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400.
77. Pascale R, Giannella M, Bartoletti M, Viale P, Pea F. Use of meropenem in treating
carbapenem-resistant Enterobacteriaceae infections. Expert Rev Anti Infect Ther. 2019
Oct;17(10):819-827.
78. コリスチンの適正使用に関する指針―改訂版―, 日本化学療法学会雑誌;63(3):290-329. 2015.
at https://www.chemotherapy.or.jp/uploads/files/guideline/colistin_guideline_update.pdf.)
79. チゲサイクリン適正使用のための手引き 日本化学療法学会雑誌; 62(3):311-366.
2014;62:311-66.
80. Tamma PD, Han JH, Rock C. et al. Carbapenem therapy is associated with improved
survival compared with piperacillin-tazobactam for patients with extended-spectrum betalactamase bacteremia. Clin Infect Dis. 2015 May;60(9):1319-1325.
81. NICE Guideline. Sepsis: recognition, diagnosis and early management. 2017. at
https://www.nice.org.uk/guidance/ng51/resources/sepsis-recognition-diagnosis-and-earlymanagement-pdf-1837508256709.)
82. Heil EL, Bork JT, Abbo LM. et al. Optimizing the Management of Uncomplicated GramNegative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process.
Open Forum Infect Dis. 2021 Oct;8(10):ofab434.
83. Poutsiaka DD, Davidson LE, Kahn KL, Bates DW, Snydman DR, Hibberd PL. Risk factors for
death after sepsis in patients immunosuppressed before the onset of sepsis. Scand J Infect
Dis. 2009;41(6-7):469-479.
84. Evans L, Rhodes A, Alhazzani W. et al. Surviving sepsis campaign: international guidelines
for management of sepsis and septic shock 2021. Intensive Care Med. 2021
Nov;47(11):1181-1247.
85. 厚生労働省 薬剤耐性緑膿菌感染症. at https://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou11/01-05-42-01.html.)
41